SCHEMBL2348575

SCHEMBL2348575

CCOC(=O)C(CCC(=O)c1ccc(F)c(F)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.41
PPARG P37231 5/20 0.41
PPARA Q07869 5/20 0.41
TRPA1 O75762 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PPARD Q03181 2/20 0.39
SCN9A Q15858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348573 1.00 MAPT (0.56) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL2575496 0.91 ALDH1A1 (0.45) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL28528491 0.91 ALDH1A1 (0.58) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL28528494 0.91 ALDH1A1 (0.58) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL2346620 0.89 ALDH1A1 (0.50) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL2346622 0.89 ALDH1A1 (0.50) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL4092905 0.88 PPARA (0.49) MAPTALDH1A1PPARGPPARATRPA1
SCHEMBL4514578 0.88 PPARA (0.49) MAPTALDH1A1PPARGPPARATRPA1
SCHEMBL2345494 0.88 ALDH1A1 (0.59) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL2345486 0.88 ALDH1A1 (0.59) MAPTALDH1A1KDM4EGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125829-B1 BICYCLIC OXOMORPHOLINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2013-01-16 EP disclosed
US-8008293-B2 Bicyclic oxomorpholine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-08-30 US disclosed
US-20100113773-A1 BICYCLIC OXOMORPHOLINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-05-06 US disclosed
US-20080207900-A1 TWO CYCLIC OXOMORPHORIN DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207900-A1 TWO CYCLIC OXOMORPHORIN DERIVATIVES OPRM1, OPRK1, OPRD1 MAPT 3723/4885ALDH1A1 2062/4885KDM4E 4439/4885
US-20100113773-A1 BICYCLIC OXOMORPHOLINE DERIVATIVE OPRM1, OPRK1, OPRD1 MAPT 2063/4885ALDH1A1 1360/4885KDM4E 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.